CBOT-P
CBOT-P
Phase 1
Phase 2
Phase 3
Phase 4
CBOT-P
CBOT-P
Chronic Pain treatment – CBOT-Pain Trial Are you or anyone you care about struggling with Chronic pain? This might be a suitable trial for you.
CBOT-P
Phase 1
Phase 2
Phase 3
Phase 4
CBOT-P
Opioid use treatment – CBOT Trial Are you or anyone you care about struggling with opioid usage? This might be a suitable trial for you.
Frequently Asked Questions
What is the duration of the study
This is a 6-month-long study with monthly follow-up visits.
What should I do during the study?
Participants will be using a new investigational at-home device that emits odors from plant-based essential oils. This device was designed to help reduce chronic pain.
What type of device is this?
It is a tabletop device that you can use in your home at a time that is convenient for you.
Will I be compensated for participating in the study?
Yes, study participation is voluntary and is compensated.
Clinical study to develop a patient-centered, cost-effective alternative strategy for rapid and sustained relief of pain and negative affect (NA) through noninvasive olfactory stimulation of the canonical secondary olfactory cortex (i.e., the OFC). Among CP conditions, chronic back pain is the most prevalent, affecting ~ 50 million Americans. Evidence from animal and human neuroimaging studies indicates that the transition from acute to CP is characterized by marked structural and functional changes in the prefrontal cortex (PFC) brain regions, which are critical to cognition and emotion regulation. As a result of these brain changes, ~ 20 million Americans with CP experience clinically significant NA states such as depression and anxiety.
Clinical study to develop a patient-centered, cost-effective alternative strategy for rapid and sustained relief of pain and negative affect (NA) through noninvasive olfactory stimulation of the canonical secondary olfactory cortex (i.e., the OFC). Among CP conditions, chronic back pain is the most prevalent, affecting ~ 50 million Americans. Evidence from animal and human neuroimaging studies indicates that the transition from acute to CP is characterized by marked structural and functional changes in the prefrontal cortex (PFC) brain regions, which are critical to cognition and emotion regulation. As a result of these brain changes, ~ 20 million Americans with CP experience clinically significant NA states such as depression and anxiety.
These NA states, in turn, are associated with higher pain intensity, lower pain tolerance, poorer response to pain treatments, sleep disturbances, and higher levels of psychiatric comorbidity. Therefore, addressing NA and PFC shrinkage is very essential to improved outcomes for people with CP. This study is to evaluate and refine our home-based product, the Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), to close these gaps in CP management. CBOT provides targeted repetitive stimulation of the orbitofrontal cortex (OFC), the anatomical secondary olfactory cortex, which plays a key role in pain and multisensory processing, pain control, decision-making, and emotion regulation.
Interested to Participate in The Study?
Are you or anyone you care about struggling with opioid usage?
